Seroquel XL approved for depression

Seroquel XL was launched in 2008 as a once-daily version of Seroquel.

Seroquel XL (prolonged-release quetiapine) has received approval as an add-on treatment for major depressive episodes in patients with major depressive disorder who have had a suboptimal response to antidepressant monotherapy.

Clinicians should consider the safety profile of prolonged-release quetiapine before initiating treatment. There is an increased risk of adverse events at higher doses; therefore, patients should be treated with the lowest effective dose and the need to increase the dose from 150mg/day to 300mg/day should be based on individual patient evaluation.

The use of prolonged-release quetiapine as an add-on to ongoing antidepressant therapy was assessed in two short-term (6-week) studies. A total of 919 patients were randomised to receive prolonged-release quetiapine 150mg or 300mg or placebo once daily; the primary endpoint was change at week 6 in Montgomery-Asberg Depression Rating Scale (MADRS) total score.

At week 6, the rate of response (defined as a ≥50 per cent decrease in MADRS total score) was 53.7% and 58.3% for quetiapine 150mg/day and 300mg/day, respectively, versus 46.2 per cent for placebo (p=0.063 and p<0.01, respectively for the two doses versus placebo). Corresponding rates of remission (MADRS total score ≤8) were 35.6% (p<0.01), 36.5% (p<0.001) and 24.1%, respectively (p<0.01 and p<0.001, respectively for the two doses versus placebo).

The long-term efficacy and safety of prolonged-release quetiapine in major depressive disorders has been evaluated in adults as monotherapy, but not as add-on therapy.

View Seroquel XL drug record

Further information: AstraZeneca

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

Pregnant woman having an ultrasound scan with a female sonographer

Valproate prescribing: plan for new regulatory measures without delay, instructs MHRA

A National Patient Safety Alert (NatPSA) has been issued...

Products coming soon - live tracker

EXCLUSIVE TO SUBSCRIBERS Monitor forthcoming UK drug...

New and deleted indications - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest changes to...

Drug shortages - live tracker

EXCLUSIVE TO SUBSCRIBERS Use our constantly updated...